| Increasing out-of-pocket health care expenditure in India-due to supply or demand T Jayakrishnan, MC Jeeja, V Kuniyil, S Paramasivam Pharmacoeconomics 1 (105), 2, 2016 | 46 | 2016 |
| The total cost of reuseable duodenoscopes-are single-use duodenoscopes the future of ERCP? HS Travis, LH Ehlers, J Thornton Pharmacoeconomics: Open Access 5 (2), 2020 | 15 | 2020 |
| The Economic Impact of Changing Levothyroxine Formulations in Difficult-to-Treat Hypothyroid Patients: An Evidence-Based Model WSCAC Riad Elmor Pharmacoeconomics: Open Access 2 (1), 10, 2017 | 11 | 2017 |
| Description of drug pricing and procurement information web portals in some Latin American countries A Acosta, S Basto, MF Fonseca, C Duran, C Vargas, J Rovira Pharmacoeconomics 3 (116), 2472-1042.1000116, 2018 | 9 | 2018 |
| Health and economic impact of relapsing forms of multiple sclerosis in Greece: the storms study J Yfantopoulos, N Grigoriadis, I Iliopoulos, K Karageorgiou, A Chantzaras, ... Pharmacoeconomics 1 (10), 10.4172, 2015 | 7 | 2015 |
| Impact of the recent changes in the pharmacy remuneration system in Portugal (2010–2014)–moving from paper to reality I Teixeira, JP Guerreiro, S Costa Pharmacoeconomics 3 (117), 2472-1042.1000117, 2018 | 2 | 2018 |
| A Critical Review of Economic Evaluations of Trastuzumab in the Treatment of Early Stage HER2 Positive Breast Cancer QNT Nguyen, HQ Nguyen, C O'Neill Pharmacoeconomics nd 2 (111), 2472-1042.1000111, 2017 | 2 | 2017 |
| Using real-world data to estimate the social security costs of retinal diseases: results from the observatory on legal blindness F Mennini, M Trabucco Aurilio, S Russo, R Migliorini, M Piccioni, F Ricci PHARMACOECONOMICS: OPEN ACCESS, 2019 | 1 | 2019 |
| Crohn’s disease treatment expenditures over fifteen years of follow-up GD Machado, B Godman, E Rahme, ML Cherchiglia, F de Assis Acurcio, ... Pharmacoeconomics: Open Access, 2018 | 1 | 2018 |
| The Seven Myths of Health and Health Care P Zweifel Pharmacoeconomics: Open Access 2 (1), 2, 2017 | 1 | 2017 |
| Treatment Pathways and Associated Costs of Advanced or Metastatic ALK+ Non-Small Cell Lung Cancer in Greece M Geitona, H Kousoulakou, I Boukovinas, V Georgoulias, P Kosmidis Pharmacoeconomics 1 (109), 2472-1042.1000109, 2016 | 1 | 2016 |
| A case report of prototheca meningitis in China Y Li, Y Zheng, G Ning Pharmacoeconomics 1 (2), 108-110, 2016 | 1 | 2016 |
| Irish GMS cost projections and its implications between 2016 and 2026 A Conway Lenihan, N Woods OMICS International, 2015 | 1 | 2015 |
| Economic Evaluation of Omalizumab in the Treatment of Severe Allergic Asthma in Adult Patients in Greece: A Cost Effectiveness Analysis of Clinical Trial and Real-Life Data V Sonathi, M Hatzikou, M Geitona, M Baldwin, E Panitti Pharmacoeconomics 1, 103, 2015 | 1 | 2015 |
| Evaluation of the Economic Impact for the Management of Patients Confirmed by COVID-19 Infection in Peru JRAG Raul Montalvo Otivo, Salome Ochoa, JF Quispe-Pari, Jorge De La Cruz Pharmacoeconomics: Open Access 5 (1), 4, 2020 | | 2020 |
| The Role of Health Technology Assessment in the Adoption of New Technologies in Diabetes Care: A Review of HTA Reports on Freestyle Libre CMSPYB Fleur Levrat-Guillen, Deirdre Blissett , Rachel Beckerman Pharmacoeconomics: Open Access 4 (1), 12, 2019 | | 2019 |
| Future Directions for DIRUM, the Database of Instruments for Resource use Measurement C Ridyard Pharmacoeconomics: Open Access 4 (1), 2, 2019 | | 2019 |
| A Systematic Literature Review and Critical Appraisal of Economic Modelling Approaches of Pharmacologic Interventions for Systemic Lupus Erythematosus (SLE) K Tolley, H Cranmer, B Desta, R Tummala, E Tafesse Pharmacoeconomics 3 (118), 2472-1042.1000118, 2018 | | 2018 |
| A Review of Pharmacoeconomics and a Discussion on Branded, Branded Generics and Generics DGSVK Sunitha Gangone Pharmacoeconomics: Open Access 2 (1), 5, 2017 | | 2017 |
| Why Do Drug Prescribing Rates Differ Across Irish Regions? MKB Lynch Pharmacoeconomics: Open Access 1 (2), 8, 2016 | | 2016 |
